Oral ixazomib-dexamethasone vs oral pomalidomide-dexamethasone for lenalidomide-refractory, proteasome inhibitor-exposed multiple myeloma: a randomized Phase 2 trial

Abstract Multiple myeloma (MM) patients typically receive several lines of combination therapy and first-line treatment commonly includes lenalidomide. As patients age, they become less tolerant to treatment, requiring convenient/tolerable/lenalidomide-free options. Carfilzomib and/or bortezomib-exp...

ver descrição completa

Detalhes bibliográficos

Principais autores:	Meletios A. Dimopoulos, Fredrik Schjesvold, Vadim Doronin, Olga Vinogradova, Hang Quach, Xavier Leleu, Yolanda Gonzalez Montes, Karthik Ramasamy, Alessandra Pompa, Mark-David Levin, Cindy Lee, Ulf Henrik Mellqvist, Roland Fenk, Hélène Demarquette, Hamdi Sati, Alexander Vorog, Richard Labotka, Jichang Du, Mohamed Darif, Shaji Kumar
Formato:	Artigo
Idioma:	Inglês
Publicado em:	Nature Publishing Group 2022-01-01
coleção:	Blood Cancer Journal
Acesso em linha:	https://doi.org/10.1038/s41408-021-00593-2
Tags:	Adicionar Tag Sem tags, seja o primeiro a adicionar uma tag!